Department of Imaging, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA 02115, USA.
AJR Am J Roentgenol. 2012 Aug;199(2):W168-74. doi: 10.2214/AJR.11.7923.
PET/CT with (18)F-FDG is a powerful tool to evaluate patients with hematologic malignancy or to assess the burden of metastatic disease from solid tumors. Metabolically active renal pathology associated with lymphoma, leukemia, or metastatic disease can be missed without close attention to both the PET and CT portions of the study because of physiologic FDG excretion in the kidneys. This article illustrates the appearance of tracer uptake and the key anatomic features of lymphoma, leukemia, and metastatic disease involving the kidney on FDG PET/CT.
Close attention to both the FDG PET and CT portions of an FDG PET/CT study is essential to evaluate the kidneys in oncology patients.
PET/CT 结合（18）F-FDG 是一种强大的工具，可用于评估血液系统恶性肿瘤患者或评估实体瘤转移疾病的负担。由于肾脏中生理性 FDG 排泄，因此如果不密切关注研究的 PET 和 CT 部分，与淋巴瘤、白血病或转移性疾病相关的代谢活跃的肾脏病理可能会被遗漏。本文说明了在 FDG PET/CT 上淋巴瘤、白血病和转移性疾病累及肾脏时示踪剂摄取的表现和关键解剖特征。
密切关注 FDG PET/CT 研究的 FDG PET 和 CT 两部分对于评估肿瘤患者的肾脏至关重要。
